These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 14970941)
21. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Ng CP; Bonavida B Adv Cancer Res; 2002; 85():145-74. PubMed ID: 12374285 [TBL] [Abstract][Full Text] [Related]
22. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Tolomeo M; Simoni D Curr Med Chem Anticancer Agents; 2002 May; 2(3):387-401. PubMed ID: 12678739 [TBL] [Abstract][Full Text] [Related]
23. Mitochondria and cancer chemoresistance. Guerra F; Arbini AA; Moro L Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):686-699. PubMed ID: 28161329 [TBL] [Abstract][Full Text] [Related]
24. Overcoming drug resistance by enhancing apoptosis of tumor cells. Giménez-Bonafé P; Tortosa A; Pérez-Tomás R Curr Cancer Drug Targets; 2009 May; 9(3):320-40. PubMed ID: 19442052 [TBL] [Abstract][Full Text] [Related]
25. Apoptosis: future directions in cancer therapy. Ravi D; Panikkar KR; Nair MK; Pillai MR Natl Med J India; 2000; 13(2):71-8. PubMed ID: 10835853 [TBL] [Abstract][Full Text] [Related]
26. Death receptor ligands, in particular TRAIL, to overcome drug resistance. de Jong S; Timmer T; Heijenbrok FJ; de Vries EG Cancer Metastasis Rev; 2001; 20(1-2):51-6. PubMed ID: 11831647 [TBL] [Abstract][Full Text] [Related]
28. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Bremer E; van Dam G; Kroesen BJ; de Leij L; Helfrich W Trends Mol Med; 2006 Aug; 12(8):382-93. PubMed ID: 16798087 [TBL] [Abstract][Full Text] [Related]
29. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453 [TBL] [Abstract][Full Text] [Related]
30. MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. Zarogoulidis P; Petanidis S; Kioseoglou E; Domvri K; Anestakis D; Zarogoulidis K Cell Signal; 2015 Aug; 27(8):1576-88. PubMed ID: 25917317 [TBL] [Abstract][Full Text] [Related]
31. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518 [TBL] [Abstract][Full Text] [Related]
32. Control of oncogenesis and cancer therapy resistance. Perona R; Sánchez-Pérez I Br J Cancer; 2004 Feb; 90(3):573-7. PubMed ID: 14760366 [TBL] [Abstract][Full Text] [Related]
33. Promise and problems of Bcl-2 antisense therapy. Reed JC J Natl Cancer Inst; 1997 Jul; 89(14):988-90. PubMed ID: 9230876 [No Abstract] [Full Text] [Related]
34. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235 [TBL] [Abstract][Full Text] [Related]
35. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation. Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192 [TBL] [Abstract][Full Text] [Related]
36. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Pistritto G; Trisciuoglio D; Ceci C; Garufi A; D'Orazi G Aging (Albany NY); 2016 Apr; 8(4):603-19. PubMed ID: 27019364 [TBL] [Abstract][Full Text] [Related]
37. Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment. Spänkuch B; Strebhardt K Curr Pharm Des; 2008; 14(11):1098-112. PubMed ID: 18473857 [TBL] [Abstract][Full Text] [Related]
38. Apoptosis and colorectal cancer: implications for therapy. Yang SY; Sales KM; Fuller B; Seifalian AM; Winslet MC Trends Mol Med; 2009 May; 15(5):225-33. PubMed ID: 19362056 [TBL] [Abstract][Full Text] [Related]
39. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893 [TBL] [Abstract][Full Text] [Related]
40. Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy. Wang Z; Liu P; Chen Q; Deng S; Liu X; Situ H; Zhong S; Hann S; Lin Y Curr Drug Targets; 2016; 17(8):853-64. PubMed ID: 25777274 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]